Orantinib
Code | Size | Price |
---|
TAR-T6184-5mg | 5mg | £108.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6184-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6184-10mg | 10mg | £128.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6184-25mg | 25mg | £193.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6184-50mg | 50mg | £306.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T6184-100mg | 100mg | £484.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
TSU-68, a excellent effective against PDGFR autophosphorylation with Ki of 8 nM, also highly inhibits Flk-1 and FGFR1 trans-phosphorylation. It shows little effect against IGF-1R, Met, Src, Lck, Zap70, Abl and CDK2 and does not suppresses EGFR.
CAS:
252916-29-3
Formula:
C18H18N2O3
Molecular Weight:
310.353
Pathway:
Tyrosine Kinase/Adaptors; Apoptosis; Angiogenesis
Purity:
0.9801
SMILES:
Cc1[nH]c(C=C2/C(=O)Nc3ccccc23)c(C)c1CCC(O)=O
Target:
Apoptosis; VEGFR; FGFR; PDGFR
References
Smolich BD, et al. Blood, 2001, 97(5), 1413-1421.
Marzola P, et al. Clin Cancer Res, 2004, 10(2), 739-750.
Kim HC, et al. Cardiovasc Intervent Radiol, 2012, 35(1), 168-175.
Laird AD, et al. Cancer Res, 2000, 60(15), 4152-4160.
Yang Y L, Cao L B, He W R, et al. Endocytosis triggers V-ATPase-SYK?mediated priming of cGAS activation and innate immune response. Proceedings of the National Academy of Sciences. 2022, 119(43): e2207280119.